AMSTERDAM—Research in myositis treatments is beginning to find its way, with investigators pursuing avenues special to the disease so therapy for patients may no longer involve piggybacking on existing treatments for other illnesses, an expert said at EULAR: the Annual European Congress of Rheumatology. “Finally, in myositis there are targets being investigated that are more…
Advocates for Arthritis Fly-In Event Benefits Rheumatology Patients
Pendaar Pooyan was diagnosed with juvenile idiopathic arthritis (JIA) in elementary school. He learned to ask for what he needed: use of a computer in class because of wrist pain and a locker that didn’t require him to bend down so far. And he learned to talk about his disease. This helped make participating for…
Virginia Society Hires Executive Director
Managing the administrative work necessary to keep members of the Virginia Society of Rheumatologists (VSR) active and engaged was proving a challenge for volunteer rheumatologists balancing their society activities with busy practice schedules. After attending several other state society meetings and talking to society leaders about the value of creating an executive director role, VSR…
Bone Mineral Density Most Important Determinant of Fracture Risk
NEW YORK (Reuters Health)—In what is believed to be the largest study investigating genetic and clinical determinants of osteoporotic fracture risk, only a genetic predisposition to low bone mineral density (BMD) had a potential causal role to play. “Notably, genetic predisposition to lower levels of vitamin D and estimated calcium intake from dairy sources were…
The FDA Denies Approval for Remoxy Extended Release; Plus Knee OA Pain Treatment Moves into Phase 3 Trials
The FDA has not approved extended release Remoxy, a gel capsule formulation of oxycodone, concluding that its potential benefits do not outweigh its risks…
Phase 2 Trial Results Suggest Baricitinib Is Effective for SLE
A recent study found that baricitinib improved symptoms of arthritis and rash in patients with active SLE, while maintaining a safety profile consistent with previous findings…
Maryland Gets an A; Most States Receive a C on ACR’s 1st Rheumatic Disease Report Card
In a first-of-its-kind report card, the ACR shows that many changes are needed for states to improve patient access to affordable and effective rheumatology care…
An Improved State of Mind?
Evidence suggesting common inflammatory pathways in RA and depression is increasing. However, this study found that improved physical health through pharmacologic treatment does not by itself improve mental health. …
AstraZeneca Lupus Drug Fails to Meet Main Goal in Study
(Reuters)—AstraZeneca’s experimental drug anifrolumab failed to meet its main target in a late-stage clinical study treating patients with moderate to severe lupus, the British drugmaker said on Friday. AstraZeneca said the drug did not meet the main goal in the final-stage of one of the two clinical trials under the TULIP program, failing to show…
Insight into Endothelial Dysfunction in Early SLE Patients without Cardiovascular Disease
The early identification of endothelial dysfunction may be useful in clinical practice to prevent SLE patients from developing atherosclerosis and cardiovascular disease. New research evaluated the use of peripheral arterial tonometry in assessing endothelial dysfunction in patients with early SLE and no cardiovascular risk factors or disease. The results: These patients showed a high rate of endothelial dysfunction and vascular stiffness…
- « Previous Page
- 1
- …
- 278
- 279
- 280
- 281
- 282
- …
- 778
- Next Page »